AsteriaRx

AsteriaRx is a pre-clinical stage biotechnology company focused on redefining musculoskeletal healing through precision-targeted drug delivery. Founded in 2025 by Dr. Danielle Benoit, the company utilizes a proprietary nanoparticle platform functionalized with a tartrate-resistant acid phosphatase (TRAP) binding peptide (TBP) to deliver therapeutic payloads directly to injured tissues. This platform, known as TendonTRAP, targets the high TRAP activity present at sites of bone fractures and healing tendons, allowing for localized delivery of small molecules (such as the GSK3β inhibitor AR28 or the anti-fibrotic agent niclosamide). By concentrating therapeutics at the injury site, AsteriaRx aims to promote regenerative healing, reduce scar tissue formation, and improve functional recovery while minimizing systemic side effects.